Plastic and Reconstructive Surgery‘s recently published annual supplement included data validating Sientra’s growing portfolio of implants and expanders as safe and innovative options for surgeons and patients undergoing aesthetic or reconstructive breast surgery.
The four-part supplement, which includes the Company’s finalized 10-year FDA Core Study, provides a comprehensive look at the long-term outcomes, surgical best practices and product differentiation of Sientra’s breast implants and tissue expanders.
